Pharmos announces results for clinical study of dexanabinol

Name, Institute, "Pharmos: Good results for clinical study of dexanabinol in coronary artery bypass graft patients. The trial provides supportive evidence of the neuroprotective effect of dexanabinol in the human brain" (22 Nov 2004, Gobes online)
Leading text: "Pharmos today announced the results of its exploratory Phase IIa clinical study of dexanabinol in coronary artery bypass graft (CABG) patients.
Dexanabinol is a synthetic non-psychotropic cannabinoid invented by Dr. Raphael Mechoulam, and licensed by Pharmos from the Hebrew University of Jerusalem. Pharmos's double blinded, placebo controlled, randomized trial enrolled 202 patients undergoing elective CABG surgery at six medical centers in Israel..."[FullText]